PharmX TechnologiesASX:PHX 40 EV-to-FCF is -90.38 as of Jul. 04, 2026. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 406 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 246305.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PharmX Technologies's Enterprise Value is A$76.64 Mil.
PharmX Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.85 Mil. Therefore, PharmX Technologies's EV-to-FCF for today is -90.38.
The historical rank and industry rank for PharmX Technologies's EV-to-FCF or its related term are showing as below:
ASX:PHX'
s EV-to-FCF Range Over the Past 10 Years
Min: -98.16 Med: -4.57 Max: 26.33
Current: -98.16
During the past 13 years, the highest EV-to-FCF of PharmX Technologies was 26.33. The lowest was -98.16. And the median was -4.57.
ASX:PHX's EV-to-FCF is ranked worse than 100% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.73
vs ASX:PHX: -98.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmX Technologies's PE Ratio (TTM) for today is calculated as:
PharmX Technologies's share price for today is A$0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmX Technologies EV-to-FCF Related Terms
PharmX Technologies EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, PharmX Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's EV-to-FCF falls into.
PharmX Technologies's current Enterprise Value is A$76.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a EV-to-FCF of -90.38 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmX Technologies and its competitors. According to the industry distribution chart, PharmX Technologies ranks #999999 out of 406 companies in the Healthcare Providers & Services industry.
Is PharmX Technologies' EV-to-FCF too high?
PharmX Technologies' current EV-to-FCF is -90.38. Based on the distribution chart, PharmX Technologies ranks #999999 out of 406 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #999999 out of 406 companies for EV-to-FCF. This places PharmX Technologies in the lower half of its industry. The industry median EV-to-FCF is 17.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.73, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current EV-to-FCF is -90.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 71.4% above its estimated fair value. The current EV-to-FCF is -90.38. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current EV-to-FCF is -90.38 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.12 is trading 71.4% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
EV-to-FCF: -90.38
GF Value™: A$0.07 vs. price of A$0.12 (71.4% above fair value)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score
Get the complete analysis for ASX:PHX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
